8-K: Stoke Therapeutics Reports Positive Q1 2025 Results and Advances Dravet Syndrome Program

Stoke Therapeutics announces positive Q1 2025 financial results, highlighted by a strategic collaboration with Biogen and progress in the Phase 3 development of zorevunersen for Dravet syndrome.

Summary

• Stoke Therapeutics reported its first quarter 2025 financial results and provided business updates.
• The company achieved regulatory alignment for the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with study start anticipated in the second quarter of 2025.
• A collaboration with Biogen was established to develop and commercialize zorevunersen, with Stoke retaining full rights in the United States, Canada, and Mexico.
• As of March 31, 2025, Stoke had $380.3 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations beyond the second half of 2027 and into launch readiness projected for mid-2028.
• First quarter revenue was $158.6 million, including $6.1 million from the Acadia Pharmaceuticals agreement and $152.4 million from the Biogen agreement.
• Net income for the first quarter was $112.9 million, or $1.90 per diluted share, compared to a net loss of $26.4 million, or $0.57 per share, for the same period in 2024.
• Research and development expenses were $32.7 million, including an $8.2 million sublicense fee related to the Biogen agreement.
• General and administrative expenses were $14.7 million due to increased personnel and launch readiness expenses.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook due to the successful collaboration with Biogen, strong financial results, and advancement of the lead drug candidate into Phase 3 development. The tone is optimistic and confident, suggesting a favorable outlook for the company.

Positives

• Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen.
• Strategic collaboration with Biogen provides significant financial resources and commercialization expertise.
• Strong cash position of $380.3 million provides a long runway for operations.
• Significant increase in revenue and net income compared to the same period in the previous year.
• Zorevunersen has been granted orphan drug designation by the FDA and the EMA.
• The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene.

Negatives

• Research and development expenses increased to $32.7 million, including a one-time $8.2 million sublicense fee.
• General and administrative expenses increased to $14.7 million due to increased personnel and launch readiness expenses.

Risks

• The company's ability to advance, obtain regulatory approval, and commercialize its product candidates is subject to risks and uncertainties.
• If Biogen were to breach or terminate the collaboration, Stoke may not obtain the anticipated financial or other benefits.
• The company and Biogen may not be successful in their development of zorevunersen, and even if successful, they may be unable to successfully commercialize it.
• Positive results in a clinical trial may not be replicated in subsequent trials, and successes in early-stage clinical trials may not be predictive of results in later-stage trials.
• The company's ability to protect its intellectual property is subject to risks.
• The company's ability to fund development activities and achieve development goals through mid-2028 is subject to risks.

Future Outlook

The company anticipates initiating the EMPEROR study in the second quarter of 2025, with data readout expected in the second half of 2027 to support global regulatory filings. The company expects its cash balance to fund operations to mid-2028.

Management Comments

• Ian F. Smith, Interim Chief Executive Officer and Director of Stoke Therapeutics, stated that the first quarter was defined by strong execution as the company advances zorevunersen into Phase 3 development for Dravet syndrome.
• He also noted that with regulatory alignment on a global Phase 3 study, a strategic collaboration with Biogen, and a balance sheet that takes the company to launch readiness, Stoke is well-positioned to deliver the first disease-modifying therapy for Dravet syndrome.

Industry Context

This announcement reflects the growing interest in RNA-based therapies for rare genetic diseases. The collaboration with Biogen, a major player in the neurology space, validates Stoke's technology and approach. The focus on Dravet syndrome, a severe and underserved condition, aligns with the industry's trend towards developing targeted therapies for unmet medical needs.

Comparison to Industry Standards

• The $165 million upfront payment from Biogen is a substantial deal, comparable to other licensing agreements in the rare disease space.
• Companies like Sarepta Therapeutics and Ionis Pharmaceuticals are also developing RNA-based therapies for genetic disorders, and Stoke's progress with zorevunersen positions them as a potential competitor.
• The projected cash runway to mid-2028 is relatively strong, providing Stoke with financial flexibility to advance its pipeline.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and the Biogen collaboration.
• Patients with Dravet syndrome and their families may benefit from the potential approval of zorevunersen.
• Employees may experience increased job security and opportunities due to the company's growth and financial stability.
• Biogen will benefit from the potential commercialization of zorevunersen in territories outside of the United States, Canada, and Mexico.

Next Steps

• Initiate the Phase 3 EMPEROR study in the second quarter of 2025.
• Continue development and commercialization efforts for zorevunersen in collaboration with Biogen.
• Advance other pipeline programs using the TANGO platform.

Key Dates

Keywords

Stoke Therapeutics, zorevunersen, Dravet syndrome, Biogen, Phase 3, EMPEROR study, RNA medicine, Financial results, Collaboration, Rare genetic diseases